Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard.
Transformation to acute leukemia (AL) is known to occur in polycythemia vera (PV) and essential thrombocythemia (ET). Myelosuppressive therapy with agents such as 32P and alkylating agents increase this risk in both disorders. The alkylating agent, uracil mustard (UM), which is an effective agent for controlling thrombocytosis, has not been reported to be leukemogenic. We have treated 29 patients with UM (9 treated continuously and 20 treated intermittently): II with PV, 16 with ET, and 2 with myelofibrosis (MF). Three patients developed AL, two after continuous therapy. These two patients with PV had received the fourth highest and highest total dose of UM, and their duration of treatment was the third and fourth longest among the nine patients treated continuously, respectively. One out of 20 patients treated intermittently with UM developed AL. This patient (3) with ET had received the highest total dose of UM, and her duration of treatment was the longest among the 20 patients treated intermittently.
Toh
B T
BT
Department of Medicine, Rush Medical College, Chicago, IL 60612.
Gregory
S A
SA
Knospe
W H
WH
D000208:Acute Disease; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007938:Leukemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy*; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*; D014499:Uracil Mustard / Q000009:adverse effects* / Q000627:therapeutic use
D014499:Uracil Mustard